Rationale and Design of a Cluster Randomized Trial of a Village Doctor-Led Intervention on Hypertension Control in China. (19th February 2021)

• Record Type: Journal Article
• Authors: Sun, Yingxian; Li, Zhao; Guo, Xiaofan; Zhou, Ying; Ouyang, Nanxiang; Xing, Liying; Sun, Guozhe; Mu, Jianjun; Wang, Daowen; Zhao, Chunxia; Wang, Jun; Ye, Ning; Zheng, Liqiang; Chen, Shuang; Chang, Ye; Yang, Ruihai; He, Jiang
• Is Part Of: American journal of hypertension. Volume 34:Number 8(2021)
• Page Start: 831
• Page End: 839
• Publication Date: 2021-02-19
• Subjects: blood pressure -- blood pressure control -- cardiovascular disease -- cluster randomized trials -- hypertension -- implementation strategies -- rural China -- village doctor; Hypertension -- Periodicals; 616.132005
• DOI: 10.1093/ajh/hpab038
• Languages: English
• ISSNs: 0895-7061

Abstract

Abstract: BACKGROUND: In China, hypertension prevalence is high and increasing while the control rate is low, especially in rural areas. Traditionally, village doctors play an important role in infectious disease control and delivering essential health services to rural residents. We aim to test the effectiveness of a village doctor-led multifaceted intervention compared with usual care on blood pressure (BP) control and cardiovascular disease (CVD) among rural residents with hypertension in China. METHODS: In the China Rural Hypertension Control Project (CRHCP), a cluster randomized trial, 163 villages were randomly assigned to the village doctor-led intervention and 163 villages to control. A total of 33, 995 individuals aged ≥40 years with an untreated BP ≥140/90 mm Hg or treated BP ≥130/80 mm Hg or with an untreated BP ≥130/80 mm Hg and a history of clinical CVD were recruited into the study. The village doctor-led multifaceted intervention is designed to overcome barriers at the healthcare system, provider, patient, and community levels. Village doctors receive training on standard BP measurement, protocol-based hypertension treatment, and health coaching. They also receive technical support and supervision from hypertension specialists/primary care physicians and performance-based financial incentives. Study participants receive health coaching on home BP monitoring, lifestyle changes, and adherence to medications. The primary outcome is BP control (<130/80 mm Hg) at 18 months in phase 1 and CVD events over 36 months in phase 2. CONCLUSIONS: The CRHCP will provide critically important data on the effectiveness, implementation, and sustainability of a hypertension control strategy in rural China for reducing the BP-related CVD burden. CLINICAL TRIALS REGISTRATION: Trial Number NCT03527719.